Altimmune reports positive 48-week Phase 2b data for pemvidutide in MASH, showing fibrosis improvement, weight loss, and ...

Altimmune said on Friday its experimental liver disease drug improved signs of scarring and health of the organ after 48 weeks of treatment in a mid-stage study. The company plans to start a ...

Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint ...

Shares of Altimmune, Inc. (ALT) jumped 16% in premarket trading on Friday after it reported positive topline results from its ...

Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH December 19, 2025 8:00 AM ...

The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...

Datta Ranpat Dev Dramatic Club (DRDDC) here today under the leadership of its president, Pushpinder Singh Charak organized a multi speciality free medical test camp in Channi Himmat. Dr. Rajesh Gupta, ...

The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to ...

Venezuela blockade: Venezuela’s government has ordered its Navy to escort ships carrying petroleum products from port, ...

The Hong Kong publisher’s fate will reveal whether democracies still have the resolve to defend their own values.

Fosun is joining the fray through its subsidiary Yao Pharma, which has granted Pfizer an exclusive worldwide license to ...